EC Clinical and Medical Case Reports

Case Report Volume 7 Issue 10 - 2024

Early Relapse of Unusual Takayasu Arteritis with Infective Endocarditis

Ayman M Samir1, Turki AlTuraifi2*, Turki A AlAmoudi3, Ahmed Afandi4, Abdullah Alawi1 and Ibraheem AlMani5

1Consultant Vascular Surgery, Vascular Surgery Division, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

2Senior Registrar General Surgery, Vascular Surgery Division, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

3Medical Intern, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

4Consultant Vascular Surgery and Kidney Transplant Surgery, Vascular Surgery Division, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

5Adult Rheumatology Fellow, Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

*Corresponding Author: Ayman M Samir, Consultant Vascular Surgery, Vascular Surgery Division, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
Received: July 09, 2024; Published: September 16, 2024



A 27-years-old female patient with lower limb rest pain and upper limb claudication. Blood culture revealed Streptococcus sanguinis. Diagnosis of Takayasu Arteritis (TA) with infective endocarditis was established based on her investigation result, patient started pulse corticosteroid then bridged to methotrexate. A few days later after response, a sudden early relapse occurred. We started Tocilizumab and she improved. Our case has an unusual presentation of TA with infective endocarditis. Tocilizumab is a promising treatment for TA especially in such cases with early relapse, but we have to emphasize its high efficacy in the long term.

 Keywords: Takayasu Arteritis; Infective Endocarditis; Vasculitis, Iliac Aneurysm; Tocilizumab; Alveolar Hemorrhage

 

  1. Isobe M. “Takayasu arteritis revisited: current diagnosis and treatment”. International Journal of Cardiology1 (2013): 3-10.
  2. Brunner J., et al. “Takayasu arteritis in children and adolescents”. Rheumatology10 (2010): 1806-1814.
  3. Johnston SL., et al. “Takayasu arteritis: a review”. Journal of Clinical Pathology7 (2002): 481-486.
  4. Grayson PC., et al. “2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis”. Arthritis and Rheumatology12 (2022): 1872-1880.
  5. Nakaoka Y., et al. “Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study”. Rheumatology9 (2020): 2427-2434.
  6. Nakaoka Y., et al. “Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial”. Rheumatology6 (2022): 2360-2368.
  7. Hellmich B., et al. “2018 Update of the EULAR recommendations for the management of large vessel vasculitis”. Annals of the Rheumatic Diseases1 (2020): 19-30.
  8. Soto M., et al. “Takayasu arteritis: clinical features in 110 Mexican mestizo patients and cardiovascular impact on survival and prognosis”. Clinical and Experimental Rheumatology 3 (2008): S9-S15.
  9. Mwipatayi BP., et al. “Takayasu arteritis: clinical features and management: report of 272 cases”. ANZ Journal of Surgery 3 (2005): 110-117.
  10. Davarpasand T., et al. “Mitral-aortic intervalvular fibrosa involvement by Takayasu’ arteritis”. International Cardiovascular Research Journal4 (2014): 181-183.
  11. An X., et al. “Takayasu arteritis presented with acute heart failure: case report and review of literature”. ESC Heart Failure4 (2017): 649-654.
  12. Khan MA., et al. “Heart failure as the initial manifestation of Takayasu’s arteritis”. International Journal of Research in Medical Sciences 1 (2016): 330.

Ayman M Samir., et al. "Early Relapse of Unusual Takayasu Arteritis with Infective Endocarditis." EC Clinical and Medical Case Reports 7.10 (2024): 01-04.